New hope for cancer patients when immunotherapy fails?
NCT ID NCT03881488
First seen Apr 20, 2026 · Last updated Jun 22, 2026 · Updated 10 times
Summary
This early-stage trial tested an experimental drug called CTX-471, given alone or with the approved drug Keytruda, in 100 adults with advanced cancers like lung cancer, melanoma, and head and neck cancer. The goal was to see if the combination is safe and tolerable for patients whose tumors no longer respond to standard PD-1/PD-L1 inhibitors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke University School of Medicine
Durham, North Carolina, 27705, United States
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
Hematology Oncology Associates Of The Treasure Coast
Port Saint Lucie, Florida, 34952, United States
-
Institute for Translational Oncology Research (ITOR)
Greenville, South Carolina, 29605, United States
-
Mary Crowley Cancer Research
Dallas, Texas, 75251, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Mt Sinai
New York, New York, 10029, United States
-
Ocala Oncology Center
Ocala, Florida, 34474, United States
-
Washington University School of Medicine, Siteman Cancer Center
St Louis, Missouri, 63110, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CTX-471 (an experimental antibody) and pembrolizumab (Keytruda)
What this could lead to
If it works, this could offer a new treatment option for people with advanced cancers that no longer respond to standard immunotherapy.
What could go wrong
This is an early Phase 1 trial, so the main goal is safety, not effectiveness. The drug may not work or could cause serious side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.